05/20/2025
4:24 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Scott Kathleen D. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/20/2025
3:48 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
SAUNDERS BRENT L (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/20/2025
3:50 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Fitzpatrick Alexander A (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/14/2025
6:01 AM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/14/2025
6:03 AM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
05/02/2025
7:05 AM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/08/2025
3:45 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Shawver Laura (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/07/2025
1:26 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Shawver Laura (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/24/2025
6:57 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Flynn James E (Filed by)
| Form SCHEDULE 13D/A | |
03/21/2025
5:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Karas Eric (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/20/2025
3:03 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Karas Eric (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
Get the Latest News and Ratings for SPRY and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for ARS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. |
03/20/2025
3:05 PM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
03/20/2025
6:02 AM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/20/2025
6:04 AM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
03/07/2025
4:12 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Shawver Laura (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/05/2025
4:18 PM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/05/2025
4:19 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Shawver Laura (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
02/04/2025
3:35 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Shawver Laura (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/03/2025
11:06 AM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Shawver Laura (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/31/2025
4:21 PM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form S-3ASR | |
01/13/2025
7:08 AM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/07/2025
5:24 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Shawver Laura (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/06/2025
3:36 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Shawver Laura (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/19/2024
3:20 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/19/2024
3:20 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/13/2024
6:52 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Dorsey Brian (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/13/2024
6:53 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Chakma Justin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/13/2024
4:24 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/12/2024
4:41 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Chakma Justin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/12/2024
4:02 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/11/2024
5:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/11/2024
5:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/11/2024
4:31 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Dorsey Brian (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/10/2024
3:48 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/10/2024
10:15 AM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Lowenthal Richard E (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/09/2024
4:43 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/09/2024
4:25 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/09/2024
11:38 AM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Shawver Laura (Reporting)
| Form 144/A | |
12/06/2024
6:15 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Chakma Justin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/06/2024
4:30 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/05/2024
4:06 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
Why July 22nd Could Mean Big Changes for Social Security (Ad) In a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Social Security — and his plan is set to roll out July 22.
What's coming next isn't about trimming waste. To see the full playbook and how it could impact everyone, click here. |
12/03/2024
4:25 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/02/2024
6:01 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/02/2024
5:22 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Shawver Laura (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/02/2024
3:42 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Karas Eric (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/27/2024
3:11 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Chakma Justin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/21/2024
3:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/21/2024
3:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/15/2024
2:21 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/13/2024
7:16 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
DEERFIELD MANAGEMENT COMPANY, L.P. (0001009258) (Reporting)
Deerfield Mgmt III, L.P. (Reporting)
Deerfield Mgmt IV, L.P. (Reporting)
Deerfield Private Design Fund III, L.P. (Reporting)
Deerfield Private Design Fund IV, L.P. (Reporting)
Flynn James E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/13/2024
6:02 AM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
11/13/2024
6:00 AM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/17/2024
3:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/17/2024
3:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/17/2024
3:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Scott Kathleen D. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/16/2024
3:01 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Scott Kathleen D. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/15/2024
10:28 AM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Tanimoto Sarina (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/15/2024
6:02 AM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/10/2024
3:27 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/10/2024
3:28 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/23/2024
3:15 PM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
09/19/2024
3:26 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/19/2024
3:29 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/19/2024
3:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Karas Eric (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/18/2024
3:06 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Karas Eric (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/12/2024
3:24 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/12/2024
3:25 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/10/2024
9:31 AM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Lowenthal Richard E (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/28/2024
3:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Thompson Peter A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/23/2024
5:41 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Thompson Peter A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/23/2024
5:38 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
ORBIMED ADVISORS LLC (Reporting)
OrbiMed Capital GP VI LLC (Reporting)
ORBIMED CAPITAL LLC (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/21/2024
5:43 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
ORBIMED CAPITAL LLC (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/21/2024
5:47 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/21/2024
5:48 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/21/2024
5:49 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Scott Kathleen D. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/21/2024
5:51 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Karas Eric (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/21/2024
5:51 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Dorsey Brian (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/20/2024
3:18 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Scott Kathleen D. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/15/2024
3:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/15/2024
3:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/15/2024
3:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Dorsey Brian (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/12/2024
6:59 AM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/18/2024
3:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/18/2024
3:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/16/2024
11:07 AM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Tanimoto Sarina (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/11/2024
4:03 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/11/2024
4:04 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/28/2024
2:15 PM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/28/2024
5:46 AM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/24/2024
4:06 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Dadoo Rajeev (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/24/2024
4:13 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Kolchinsky Peter (Reporting)
RA Capital Healthcare Fund LP (Reporting)
RA CAPITAL MANAGEMENT, L.P. (Reporting)
RA Capital Nexus Fund II, L.P. (Reporting)
Shah Rajeev M. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
"I'm risking my reputation on this" (Ad) Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented.
And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots…
What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book. Claim your FREE copy of Crypto Revolution now. |
06/21/2024
4:00 PM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/17/2024
7:47 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Pratik Shah Living Trust dated June 15, 2011 (Filed by)
| Form SC 13D/A | |
06/17/2024
5:39 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Shah Pratik (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/13/2024
3:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
